CTX-712 approval filing plan for relapsed/refractory AML
A focus on developing CTX-712 for relapsed/refractory AML as the priority indication and aiming to file for approval by 2026–2028, and subsequently in the second half of 2028, by using accelerated approval programs and other measures.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.